Inhaled corticosteroids are the single most effective controller therapy for persistent asthma, and their benefits extend well beyond day-to-day symptom relief. Regular use reduces airway inflammation, cuts the risk of severe flare-ups, and, according to multiple population-level studies, can lower asthma hospitalizations by as much as 80 percent. Yet the story is more layered than “take ICS, breathe better.” How much you need, when the payoff plateaus, whether they help in COPD, and what risks come along for the ride all depend on factors that have only recently become clear.
How ICS Tame Airway Inflammation
The core job of an inhaled corticosteroid is to quiet inflammation inside the airways. In asthma, the lining of the bronchial tubes becomes chronically inflamed, swollen, and twitchy, making them overreact to triggers like allergens, cold air, or exercise. ICS suppress that inflammation mainly by switching off the genes responsible for producing inflammatory signals. The result is less swelling, less mucus, and airways that are far less prone to spasm.
Because ICS are delivered directly to the lungs rather than swallowed or injected, they reach inflamed tissue at high concentrations while exposing the rest of the body to relatively little steroid. That targeted delivery is what separates them from oral corticosteroids like prednisone, which work through the same basic mechanism but flood every organ with the drug. The local delivery means ICS can be used daily for years with a side-effect profile that oral steroids cannot match.
Reducing Hospitalizations and Deaths in Asthma
The most dramatic benefit of ICS is their impact on the worst outcomes. A review of eight cohort and population-level studies found that regular ICS use could decrease asthma hospitalizations by up to 80 percent, and that even low doses significantly reduced asthma deaths.1PubMed. Inhaled corticosteroids: impact on asthma morbidity and mortality That finding has held up over the years. More recent evidence confirms a compelling role for ICS in reducing asthma mortality, though because fatal asthma attacks are fortunately rare, a prospective randomized trial proving the mortality benefit is unlikely ever to be run.2European Respiratory Journal. Asthma progression and mortality: the role of inhaled corticosteroids
These are population-level findings, meaning the benefit shows up most clearly when researchers look at large groups of patients over time. For an individual, the practical takeaway is straightforward: staying on a prescribed ICS consistently is one of the most reliable ways to stay out of the emergency department.
As-Needed ICS for Mild Asthma
For decades, guidelines told people with even mild asthma to use their ICS inhaler every single day, whether they felt symptomatic or not. That changed after two landmark trials showed that using a combination inhaler containing budesonide and formoterol only when symptoms appeared could work just as well for many mild-asthma patients.
In one trial, as-needed budesonide-formoterol reduced the annual rate of severe flare-ups by about 64 percent compared to using a short-acting bronchodilator alone, and the rate was comparable to what daily maintenance budesonide achieved.3PubMed. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma A second trial confirmed the pattern: severe exacerbations were 60 percent lower with as-needed budesonide-formoterol than with as-needed albuterol alone, and were comparable to those seen with daily maintenance budesonide.4PubMed. Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma This approach, sometimes called MART (maintenance and reliever therapy), means that the anti-inflammatory steroid arrives in the lungs at the moment inflammation is flaring, rather than being taken on a fixed schedule that many patients struggle to follow.
The shift is significant because adherence to daily inhalers in real life is notoriously poor. A Japanese study found that both adherence and inhaler-handling errors were independent predictors of whether a patient’s asthma was actually controlled.5Internal Medicine. Influence of Adherence to Inhaled Corticosteroids and Inhaler Handling Errors on Asthma Control in a Japanese Population If you only need to use the device when you feel symptoms coming on, the compliance barrier drops considerably.
Most of the Benefit Comes at Low Doses
One of the most important and underappreciated facts about ICS is how flat the dose-response curve is. A meta-analysis of fluticasone propionate in adolescents and adults found that roughly 80 to 90 percent of the maximum therapeutic benefit was achieved at just 100 to 250 micrograms per day, and that doses above about 500 micrograms per day added almost nothing.6PubMed Central. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis A more recent review echoed this, explaining that the plateau occurs because even low ICS doses occupy more than 90 percent of the glucocorticoid receptors in the airways, leaving very little room for additional benefit when the dose climbs higher.7Academic Medicine & Surgery. High vs. Low-Dose Inhaled Corticosteroids: Effects on Lung Function and Adverse Outcomes in Asthma
This matters for safety. The side effects of ICS are dose-dependent, so pushing into high-dose territory delivers diminishing therapeutic returns while the risk of systemic effects keeps climbing. For most people with asthma, staying at a low-to-moderate dose captures nearly all of the drug’s anti-inflammatory power.
Benefits Beyond Inflammation: Airway Remodeling
Chronic asthma does not just cause temporary swelling. Over time, repeated bouts of inflammation lead to structural changes in the airway walls, including thickening of the basement membrane beneath the airway lining. This remodeling contributes to the progressive loss of lung function some asthma patients experience over the years.
ICS appear to partially reverse this process, though it takes time. A controlled trial of fluticasone propionate found that basement-membrane thickness decreased significantly, but only after 12 months of treatment. About a third of the early improvement in airway hyperresponsiveness was linked to reduced inflammation, but the larger and more progressive gains came later, associated with the reversal of structural remodeling itself.8PubMed Central. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma The implication is that the full benefit of ICS does not show up in weeks. Patients who give up after a few months because they feel “fine” may miss out on the structural repair that protects lung function over years and decades.
ICS in COPD: A More Selective Benefit
In chronic obstructive pulmonary disease, the picture is more complicated. Unlike asthma, where nearly everyone benefits from ICS, COPD is a more heterogeneous condition. Many COPD patients have inflammation driven by neutrophils rather than eosinophils, and ICS do not work well against neutrophilic inflammation. The key question has become: which COPD patients actually benefit?
The answer increasingly centers on blood eosinophil counts. A meta-analysis found that COPD patients whose blood eosinophils were at or above 2 percent experienced a 17 percent reduction in moderate-to-severe exacerbations with ICS therapy compared to those not using ICS.9PubMed Central. Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis Post-hoc analyses of major clinical trials consistently show the same trend: the higher the eosinophil count at baseline, the greater the benefit from adding ICS to a bronchodilator regimen.10PubMed Central. Blood Eosinophil Counts in Chronic Obstructive Pulmonary Disease: A Biomarker of Inhaled Corticosteroid Effects
When ICS are combined with two long-acting bronchodilators in a “triple therapy” regimen, the exacerbation reductions can be substantial. A systematic review found that triple therapy reduced the annual rate of moderate-to-severe exacerbations by 15 to 52 percent compared with dual bronchodilator therapy alone.11PubMed Central. Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review For COPD patients with elevated eosinophils and frequent flare-ups, the addition of ICS can be genuinely transformative.
Using Exhaled Nitric Oxide to Fine-Tune Treatment
Eosinophil counts are not the only way to guide ICS use. Fractional exhaled nitric oxide, a gas you can measure with a simple breath test, reflects eosinophilic inflammation in the airways. A meta-analysis in COPD patients found that ICS therapy significantly reduced exhaled nitric oxide levels, and that patients who started with high baseline readings tended to show better lung-function improvements with treatment.12PubMed Central. Predictors of fractional exhaled nitric oxide response to inhaled corticosteroid therapy in chronic obstructive pulmonary disease: A systematic review and meta-analysis
In asthma, a trial tested whether adjusting the ICS dose based on exhaled nitric oxide readings could reduce the total amount of steroid a patient needed. It worked: the group whose doses were guided by nitric oxide measurements ended up on about 40 percent less fluticasone than the group managed by conventional methods, with no meaningful difference in asthma control or exacerbation rates.13PubMed. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma The promise of this kind of biomarker-guided dosing is that patients can get the inflammatory control they need without being exposed to more steroid than necessary.
Safety Trade-Offs Worth Knowing About
ICS are generally safe, especially at low-to-moderate doses, but they are not risk-free. The side effects fall into two categories: local effects in the mouth and throat, and systemic effects when enough steroid is absorbed into the bloodstream.
The most common local problem is oral thrush, a yeast infection in the mouth caused by the drug suppressing local immune defenses. Preventive measures are simple and effective: using a spacer device with a metered-dose inhaler, rinsing the mouth after each use, and, for denture wearers, proper denture care.14PubMed Central. Non-Pharmacological Interventions to Prevent Oropharyngeal Candidiasis in Patients Using Inhaled Corticosteroids: A Narrative Review Hoarseness is another local nuisance, caused by the steroid depositing on the vocal cords.
Systemic risks rise with dose and duration. In COPD patients, current ICS use was associated with a 69 percent increase in the rate of serious pneumonia in a large observational study.15PubMed Central. Inhaled corticosteroids in COPD and the risk of serious pneumonia This pneumonia risk is one of the main reasons clinicians now try to limit ICS use in COPD to patients whose eosinophil profile suggests they will actually benefit. At high doses over prolonged periods, ICS can also affect the bones, contributing to conditions like osteoporosis.16PubMed Central. Inhaled corticosteroids and bone health And high-dose ICS carry a measurable risk of adrenal insufficiency, where the body’s own cortisol production is suppressed, with one study finding roughly a twofold increase in risk among patients on the highest doses.17European Respiratory Journal. The use of inhaled corticosteroids and the risk of adrenal insufficiency
Growth in Children
Parents often worry about putting a child on a daily steroid, and the concern is not unfounded. A Cochrane systematic review confirmed that ICS can cause a small reduction in growth velocity during the first year of use. However, the suppression was not cumulative beyond that first year, meaning children did not continue falling further behind over time.18Cochrane Database of Systematic Reviews. Inhaled corticosteroids compared with placebo or non-steroidal drugs versus children with persistent asthma: effects on growth The review’s authors concluded that the well-established benefits of ICS in controlling persistent asthma likely outweigh the risk of a small, non-progressive growth effect, but recommended prescribing at the lowest effective dose. For most children, this amounts to a slight reduction in final adult height on the order of about a centimeter, which is a meaningful consideration but one that needs to be weighed against the very real dangers of uncontrolled asthma.
Stepping Down or Stopping ICS in COPD
Because of the pneumonia and other systemic risks, the question of whether and when to withdraw ICS from COPD patients has received serious attention. A European Respiratory Society guideline found that for patients with blood eosinophil counts below 300 cells per microliter, withdrawing ICS had no effect on the rate of exacerbations. But for those with eosinophil counts at or above that threshold, stopping ICS led to a 63 percent increase in flare-ups.19European Respiratory Journal. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline Randomized trials and real-world studies have confirmed that ICS can be safely withdrawn in certain COPD patients, particularly those without eosinophilic inflammation who were started on ICS based on older prescribing habits that did not distinguish between inflammatory subtypes.20International Journal of Chronic Obstructive Pulmonary Disease. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice
The practical message is that ICS in COPD is not all-or-nothing. A blood eosinophil count is a simple and widely available test that helps clinicians decide who should start ICS, who should stay on them, and who can safely stop.
Particle Size and Why Your Inhaler Device Matters
Not all ICS inhalers deliver drug to the same parts of the lung. Standard formulations produce relatively large particles that deposit mainly in the large central airways. Extrafine formulations produce smaller particles that penetrate deeper, reaching the small airways where a substantial portion of asthma inflammation actually lives. A functional respiratory imaging study found that an extrafine dry powder inhaler delivered roughly five times more drug to the peripheral (small) airways than a conventional large-particle device at the same inspiratory flow rate.21PubMed Central. Targeting the Small Airways with Inhaled Corticosteroid/Long-Acting Beta Agonist Dry Powder Inhalers: A Functional Respiratory Imaging Study Clinical data support the idea that this improved deposition translates to better asthma control for some patients.22Proceedings of Singapore Healthcare. The effect of fine-particle size and extrafine particle size inhaled corticosteroid in reducing airway resistance in asthmatic patients
The type of inhaler device also matters for the environment. Metered-dose inhalers use hydrofluorocarbon propellants that are potent greenhouse gases. Dry powder inhalers, which are breath-actuated and propellant-free, have a dramatically smaller carbon footprint. One analysis estimated that switching to non-propellant inhalers could reduce inhaler-related greenhouse gas emissions by 85 percent without compromising treatment quality.23BMJ Open Respiratory Research. Thoughtful prescription of inhaled medication has the potential to reduce inhaler-related greenhouse gas emissions by 85% Real-world evidence also suggests that once-daily combination dry powder inhalers improve adherence compared to twice-daily regimens, so the switch can benefit both the patient and the planet.24PubMed. The environmental impact of inhalers for asthma: A green challenge and a golden opportunity
Swallowed Corticosteroids for Eosinophilic Esophagitis
An unexpected use of inhaled corticosteroid formulations has emerged in gastroenterology. Eosinophilic esophagitis is a condition where eosinophils infiltrate the lining of the esophagus, causing difficulty swallowing and food impaction. For years, clinicians improvised by having patients swallow aerosolized fluticasone or mix budesonide into a slurry instead of inhaling it, coating the esophagus with the steroid. A network meta-analysis confirmed that both budesonide and fluticasone are effective at inducing remission of eosinophilic esophagitis, regardless of the specific formulation used.25PubMed Central. Comparative Efficacy and Safety of Swallowed Topical Corticosteroids in Eosinophilic Esophagitis: A Network Meta-Analysis More recently, purpose-built esophagus-targeted formulations have arrived, with response rates reaching up to 85 percent. An orodispersible budesonide tablet became the first formally approved medication for eosinophilic esophagitis in Europe in 2018.26PubMed Central. Treatment of eosinophlic esophagitis with swallowed topical corticosteroids Long-term maintenance data remain thin, but for patients struggling with this condition, the availability of a targeted corticosteroid therapy has been a major development.
Genetic Variation in ICS Response
Not everyone responds equally to ICS, and part of the explanation is genetic. Research into the gene encoding corticotropin-releasing hormone receptor 1 (CRHR1) found that people carrying certain variants had a two- to fourfold greater improvement in lung function with ICS compared to those without the variants. The association held across three separate asthma populations.27PubMed. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids The pharmacogenomics of ICS is still in its early stages, and no genetic test is routinely ordered before prescribing an inhaler. But the finding helps explain why some patients seem to respond brilliantly to even low ICS doses while others remain poorly controlled despite escalating therapy. As genetic testing becomes cheaper and more integrated into clinical care, it is plausible that ICS prescribing will eventually be personalized on the basis of a patient’s genomic profile rather than a one-size-fits-all stepwise approach.